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West Nile Fever in Czechland
To the Editor: After heavy rains in July 1997,
extensive floods occurred along the Morava
River, Czech Republic. Populations of Aedes
mosquitoes increased rapidly in the flooded
areas, prompting surveillance for mosquito-
borne virus infections in the Breclav area, South
Moravia. We collected 11,334 female mosquitoes
(9,100  Aedes vexans, 917 Ae. cinereus, 11
Ae. cantans, 1,074 Ae. sticticus, and 232 Culex p.
pipiens) from July through September 1997 and
tested them for virus in 117 monospecific pools
by intracranial inoculation of suckling mice.
Seven virus isolates were obtained and identified
by complement-fixation and neutralization tests.
Six isolates (five from Ae. vexans, one from Ae.
cinereus) were identified as the bunyavirus
Tahyna, California serogroup, and one (strain
97-103 from 57 C. p. pipiens collected at Lanzhot,
48o40'N, 16o56'E, on September 17) was
identified as the flavivirus West Nile (1). A
crossed comparison of 97-103 and topotype Eg-
101 (2) West Nile virus strains and their antisera
(prepared in mice by three intraperitoneal doses
at weekly intervals) by plaque reduction
neutralization (PRN) on XTC-2 cells (3,4) showed
their antigenic relationships: reciprocal titers of
homologous/heterologous sera were 512/512 in
Eg-101 and 512/64 in 97-103. Strain 97-103 has
lower virulence than Eg-101 in that it does not
kill adult ICR mice and may represent a subtype
of West Nile virus.
Blood samples were obtained from 619
persons seeking treatment at hospital and
outpatient clinics in the Breclav area from June
23 through September 29, 1997. Sera were
inactivated at 56°C for 30 minutes, diluted 1:8,
and assayed by PRN for antibodies against c. 30
plaque-forming units (PFU) per well of West Nile
virus strains Eg-101 and 97-103. All sera causing
90% reduction of PFU at 1:8 dilution were
titrated, and the highest serum dilution showing
50% PFU reduction was regarded as the titer.
Antibodies neutralizing West Nile virus were
detected in 13 (2.1%) persons: 2.8% of 179 male
and 1.8% of 440 female. Persons with detectable
West Nile virus antibody were questioned about
their health history during the previous 5 years,
and their medical records were reviewed; none
recalled having had tickborne encephalitis
(Central-European encephalitis [CEE] virus is
the only other flavivirus present in Czechland) or
having been vaccinated against CEE or yellow
fever virus. Titers of PRN antibodies to CEEV
were all below 16. Two of the seropositive
persons had traveled abroad during the last 5
years: one to Croatia in 1996, and one to South
Australia during 1951 to 1994.
Paired serum samples were obtained from 72
of the 619 persons examined. A significant
increase (³4 times) in antibody titer against West
Nile virus between the first (acute-phase) and
second (convalescent-phase) samples was de-
tected four times: in 2 of 41 young persons (£16
years of age) and in 2 of 31 adults (>16 years of
age). Among the four seroconverting persons,
only the two children had clinical symptoms
compatible with West Nile fever. A 9-year-old
boy had fever (39oC) for 4 days, sore throat,
headache, muscle ache, pronounced fatigue, and
nausea lasting approximately 6 days, with
recovery after 13 days. Neutralizing antibodies
to West Nile virus, Eg-101 and 97-103, were 64
and 32 on July 22 and 512 and 256 on August 4,
respectively. A 9-year-old girl had fever (38°C-
39°C) for 3 days, sore throat, headache, muscle
ache, pronounced fatigue, nausea, vomiting,
maculopapular rash (including flushed face),
and slightly enlarged inguinal lymph nodes. The
illness lasted approximately 7 days, with
complete recovery after 17 days. Neutralizing
antibodies to West Nile virus, Eg-101 and 97-103,
were 64 and 32 on August 6 and 256 and 128 on
August 20, respectively. Of the remaining nine
seropositive persons lacking paired serum
samples, one had severe headache, muscle ache,
prolonged fatigue, nausea, pain on eye move-
ment, maculopapular rash, and insomnia in
summer of 1997. Two other persons had had
summer fever (sore throat and lymphadenitis;
headache with pain on eye movement) in 1997.
The other persons who seroconverted did not
report any substantial illness. In total, clinical
symptoms in five persons are compatible with
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These are the first reported human cases of
West Nile fever in Central Europe (5); an
extensive outbreak occurred in Romania in 1996,
with approximately 500 patients hospitalized
and a 4% to 8% fatality rate (6,7). West Nile virus
should be viewed as a potential agent of local
sporadic cases, clusters, or outbreaks, even in
temperate Europe. Environmental factors (in-
cluding human activities) that enhance vector
population densities (heavy rains followed by
floods, irrigation, higher than usual tempera-
tures due to global warming) might produce an
increased incidence of West Nile fever and other
new or reemerging mosquito-borne diseases.
Surveillance for West Nile fever should monitor
population density and infection rate of principal
vectors, antibodies in vertebrates and exposed
human groups, and routine diagnosis of human
infections.
Zdenek Hubálek, Jirí Halouzka, and
Zina Juricová
Institute of Vertebrate Biology, Academy of Sciences,
Brno, Czech Republic
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Ofloxacin-Resistant Vibrio cholerae O139
in Hong Kong
To the Editor: Unexpected outbreaks of cholera
occurred in many areas of the world in 1997-98,
partly because of weather changes associated
with the El Niño phenomenon (1). Outbreaks
caused by antibiotic-resistant Vibrio cholerae O1
and O139 have been documented in the Indian
subcontinent (2-4), Africa (5), and Ukraine (6).
In Hong Kong, nonduplicate bacterial
strains of V. cholerae O1 and O139 isolated from
patients and environmental sources and re-
ceived in the Public Health Laboratory between
January 1, 1993, and June 30, 1998, were
identified by conventional biochemical tests (7,8)
and API 20E (bioMerieux, France); serotyped by
slide agglutination with polyvalent O1 and
mono-specific Inaba and Ogawa antisera
(Murex, Dartford, United Kingdom); and
checked with O139 antiserum (Denka Seiken,
Tokyo, Japan). Biotyped and antibiotic suscepti-
bilities were determined by the Kirby-Bauer
disk-diffusion assay (8-10). Antibiotics tested
included chloramphenicol and tetracycline (from
1993 to 1996) and ofloxacin (added in routine
testing from 1997). V. cholerae isolates available
for further study were tested with the standard
broth microdilution method (11) to measure
minimum inhibitory concentrations (MICs) of
susceptibilities to chloramphenicol, tetracycline,
and ofloxacin.
No antibiotic resistance was seen in
V. cholerae isolates in testing conducted from
1969 to 1995. The first V. cholerae isolate with
reduced susceptibility to chloramphenicol but
sensitive to tetracycline was encountered in
Hong Kong in 1996. This O1 El Tor Ogawa strain
was imported from Nepal. Since then, more O1
strains were isolated that exhibited reduced
antibiotic susceptibilities to chloramphenicol
and tetracycline but not to ofloxacin (12). In May
1998, seven V. cholerae O139 strains were
isolated that displayed patterns of antibiotic
susceptibilities strikingly different from those of
O1 isolates; the former were all sensitive to
tetracycline but showed reduced susceptibilities
to chloramphenicol and ofloxacin. All V. cholerae
O1 strains tested have been susceptible to
ofloxacin; O1 isolates falling into intermediate
categories for chloramphenicol and tetracycline
susceptibilities (31% and 27.6%, respectively)
were common.
The first isolate of V. cholerae O139 in Hong
Kong came from the imported case of a patient
who had traveled to other provinces of China
(13,14). Isolation of O139 continued sporadically
since then, with six cases between 1993 and the